Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments

Stock Track

04/01

PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.

The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.

Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a "Buy" rating has been maintained, driving the stock's upward movement.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1135212271"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135212271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135212271?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135212271","market":"sg","top_or_hot":-1,"title":"Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments","media":"Stock Track","content":"<p>PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.</p><p>The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.</p><p>Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a \"Buy\" rating has been maintained, driving the stock's upward movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-01 15:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.</p><p>The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.</p><p>Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a \"Buy\" rating has been maintained, driving the stock's upward movement.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉醫療-B","start_time":0,"source_url":"","article_id":"1135212271","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135212271","pubTimestamp":1775028966,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.The surge follows the company's release of its annual results, which showed revenue growth of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"个股赛道|沛嘉-B盘中大涨7.75%TAVR和神经介入板块强劲年度业绩和增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"PEIJIA-B's stock soared 7.75% during intraday trading on Wednesday, reflecting strong investor sentiment.The surge follows the company's release of its annual results, which showed revenue growth of 15.82% year-on-year to RMB 713 million. Revenue from TAVR-related products increased by 11.6% to RMB 290 million, while neurointervention products revenue rose 18.9% to RMB 423 million, with segment profit jumping 86.6% to RMB 97.2 million.Institutional analysis highlights that the TAVR segment is expected to benefit from volume growth after national price negotiations and the commercialization of the regurgitation valve TaurusTrio in 2026. The neurointervention segment, with coils providing stable cash flow and DCwire micro-guidewires receiving FDA approval, is set to contribute overseas revenue. The company aims to achieve breakeven within the year, and with new products like TaurusNXT and GeminiOne TEER in registration, along with advancing clinical pipelines, a \"Buy\" rating has been maintained, driving the stock's upward movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}